

## DAFTAR PUSTAKA

- American Cancer Society, 2011 – 2012. *Breast Cancer Facts & Figures*,. Atlanta: American Cancer Society; p.1-28.
- Baird RD, Caldas C, 2013. *Genetic heterogeneity in breast cancer: the road to personalized medicine?* BMC Med 11. p. 151.
- Blenkiron C, et all, 2007. *MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype*. Genome Biol 8: p. 214.
- Bosetti C, Bertuccio P, Levi F, Chatenoud L, Negri E, La Vecchia C, 2009. *The decline in breast cancer mortality in Europe: An Update*. The Breast. 2012;21 (1). p. 77-82.
- Bushati N, Cohen SM, 2007. *microRNA functions*. Annu Rev Cell Dev Biol 23. p. 175-205.
- Calin GA, Croce CM, 2006. *MicroRNA signatures in human cancers*. Nat Rev Cancer 6. p. 857-866.
- Calin GA et all, 2005. *A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia*. N Engl J Med 353. p. 1793-1801.
- Calin GA et all, 2002. *Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia*. Proc Natl Acad Sci U S A 99. p. 15524-15529.
- Coughlin SS, Ekwueme DU, 2009. *Breast cancer as a global health concern*. Cancer Epidemiology 33. p. 315- 318
- Croce CM, 2009. *Causes and consequences of microRNA dysregulation in cancer*. Nat Rev Genet 10. p. 704-714.
- Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, et al, 2000. *The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients*. Cancer Research, (60). p. 636-43.
- Harbeck N, Kates RE, Schmitt M, 2002. *Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination*. Journal of Clinical Oncology.;(20). p. 1000-7.
- Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, 2001. *Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk*

- according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Research.; (62). p. 4617-4622.*
- Iorio MV et al, 2005. *MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65. p. 7065-7070.*
- Janicke F, Prechtel A, Thomssen C, Harbeck N, Meisner C, Untch M, et al, 2001. *Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. Journal of National Cancer Institute;(93). p. 913-20.*
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, 2011. *Global Cancer Statistic. Cancer Journal for Clinician 61. p. 69-90.*
- J Barinoff et al, 2013. *Clinicopathological differences between breast cancer in patients with primary metastatic disease and those without : A multicentre study. European Journal of Cancer 49. p. 305-311.*
- Kamila Naxerova, 2020. *Defining the role of lymph node metastasis in systemic breast cancer evolution. EbioMedicine; 57: 102852.*
- Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, et al. 2001. *Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clinical Cancer Research;(7). p. 2448-57.*
- Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen I.J, Thomssen C, 2001. *Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. Journal of National Cancer Institute; (94). p. 116-128.*
- TCGA, 2012. *Comprehensive molecular portraits of human breast tumours. Nature 490. p. 61-70.*
- Victoria Sopik, Steven A Narod, 2018. *The correlation between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Research and Treatment 170(3). p. 647-656.*
- Zhang Let et al, 2006. *microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 103. p. 9136-9141.*